How to buy Agenus shares | $4.07

Own Agenus shares in just a few minutes. Share price changes are updated daily.

Posted

Fact checked

Agenus Inc (AGEN) is a leading biotechnology business based in the US. It opened the day at $4.05 after a previous close of $4.05. During the day the price has varied from a low of $3.98 to a high of $4.13. The latest price was $4.07 (25 minute delay). Agenus is listed on the NASDAQ and employs 328 staff. All prices are listed in US Dollars.

How to buy shares in Agenus

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: AGEN in this case.
  5. Research Agenus shares. The platform should provide the latest information available.
  6. Buy your Agenus shares. It's that simple.

How has Coronavirus impacted Agenus's share price?

Since the stock market crash in March caused by coronavirus, Agenus's share price has had significant positive movement.

Its last market close was $4.2, which is 16.19% up on its pre-crash value of $3.52 and 130.77% up on the lowest point reached during the March crash when the shares fell as low as $1.82.

If you had bought $1,000 worth of Agenus shares at the start of February 2020, those shares would have been worth $540.76 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,141.31.

Agenus share price

Use our graph to track the performance of AGEN stocks over time.

Agenus shares at a glance

Information last updated 2020-09-29.
Open$4.05
High$4.13
Low$3.98
Close$4.07
Previous close$4.05
Change $0.02
Change % 0.494%
Volume 1,255,318
Information last updated 2020-10-14.
52-week range$1.82 - $5.63
50-day moving average $4.3686
200-day moving average $3.5436
Wall St. target price$8
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.906
Promoted
eToro Free Stocks

Invest in Agenus shares with 0% commission

Other fees may apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • If your trades get copied you can earn extra money
  • Create an account today in a few minutes

Share dealing platform comparison

Table: sorted by promoted deals first
Data indicated here is updated regularly
Name Product Price per trade Frequent trader rate Platform fees Brand description
Fineco
£2.95
£2.95
Zero platform fee
Your first 50 trades are free with Fineco, until 31/12/2020. T&Cs apply.
Fineco Bank is good for share traders and investors looking for a complete platform and wide offer. Capital at risk.
IG
0% commission on US shares, and £3 on UK shares
From £5
£0 - £24 per quarter
IG is good for experienced traders, and offers learning resources for beginners, all with wide access to shares, ETFs and funds. Capital at risk.
eToro Free Stocks
0% commission, no markup, no ticket fee, no management fee
N/A
Withdrawal fee & GDP to USD deposit conversion
Capital at risk. 0% commission but other fees may apply.
Hargreaves Lansdown Fund and Share Account
£11.95
£5.95
No fees
Cashback offer: Take control of your money and transfer investments to HL – get cashback as a thank you. Terms apply.
Hargreaves Lansdown is the UK's number one platform for private investors, with the depth of features you'd expect from an established platform. Capital at risk.
Interactive Investor
From £7.99 on the Investor Service Plan
From £7.99 on the Investor Service Plan
No transfer fees or exit fees. £9.99 a month on the Investor Service Plan
Open an ISA, Trading Account or SIPP you will get £100 of free trades to buy or sell any investment (new customers only).
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum deposit Maximum annual fee Price per trade Brand description
Moneyfarm stocks and shares ISA
£1500
0.75%
£0
Hargreaves Lansdown stocks and shares ISA
£100
0.45%
£11.95
Hargreaves Lansdown is the UK's biggest wealth manager. It's got everything you'll need, from beginners to experienced investors. Capital at risk.
Interactive Investor stocks and shares ISA
Any lump sum or £25 a month
£119.88
£7.99
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
Saxo Markets stocks and shares ISA
No minimum deposit requirement
0.12%
£8.00
Saxo Markets offers a wide access to a range of stocks, ETFs and funds. Capital at risk.
AJ Bell stocks and shares ISA
£500
0.25%
£9.95
AJ Bell is a good all-rounder for people who to choose between shares, funds, ISAs and pensions. Capital at risk.
Fidelity stocks and shares ISA
£1000 or a regular savings plan from £50
0.35%
£10.00
Fidelity is another good all-rounder, offering a good package at a decent price. Not suited for trading shares. Capital at risk.
Nutmeg stocks and shares ISA
£100
0.75%
£0
Nutmeg offers three types of portfolios. Choose the one that goes with your investment style. Capital at risk.
Legal & General stocks and shares ISA
Legal & General stocks and shares ISA
£100 or £20 a month
0.61%
N/A
Legal & General is a big financial services company which offers insurance, lifetime mortgage, pensions and stocks and shares ISAs. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum investment Choose from Annual fee Brand description
Moneyfarm Pension
£1,500 (initial investment)
7 funds
0.35%-0.75%
Moneyfarm has pensions that are matched against your risk appetite, goals and planned retirement date. Capital at risk.
AJ Bell Pension
£1,000
Over 2,000 funds
0.05-0.25%
AJ Bell has two different pension options, a self managed pension and one that is managed for you. Capital at risk.
PensionBee Pension
No minimum
7 funds
0.5% - 0.95%
Pension Bee is a newbie in the pension market. It helps consolidate your pension plans into one place. Capital at risk.
Hargreaves Lansdown Pension
£100 or £25 a month
2,500 funds
0-0.45%
Hargreaves Lansdown is the UK's biggest wealth manager. It's got three different retirement options. Capital at risk.
Interactive Investor Pension
Any lump sum or £25 a month
Over 3,000 funds
£10/month
interactive investor is a flat-fee platform, which makes it cost effective for larger portfolios. Capital at risk.
Saxo Markets Pension
Saxo Markets Pension
£10
Over 11,000 funds
No annual fee
Saxo Markets gives flexibility and control over your investment strategy. Capital at risk.
Moneybox Pension
£1
3 funds
0.15% - 0.45% charged monthly
Manage your money with an easy-to-use Moneybox app. Capital at risk.
loading

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Capital is at risk.

Is it a good time to buy Agenus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Agenus price performance over time

Historical closes compared with the last close of $4.07

1 week (2020-10-15) -4.68%
1 month (2020-09-25) 1.24%
3 months (2020-07-24) 25.62%
6 months (2020-04-24) 45.88%
1 year (2019-10-25) 68.88%
2 years (2018-10-25) 127.37%
3 years (2017-10-25) 9.12%
5 years (2015-10-23) -19.09%

Agenus financials

Revenue TTM $96.5 million
Gross profit TTM $-18,291,000
Return on assets TTM -35.24%
Return on equity TTM 0%
Profit margin -173.74%
Market capitalisation $757.6 million

TTM: trailing 12 months

How to short and sell Agenus shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "AGEN.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 23.1 million Agenus shares held short by investors – that's known as Agenus's "short interest". This figure is 0.4% up from 23.1 million last month.

There are a few different ways that this level of interest in shorting Agenus shares can be evaluated.

Agenus's "short interest ratio" (SIR)

Agenus's "short interest ratio" (SIR) is the quantity of Agenus shares currently shorted divided by the average quantity of Agenus shares traded daily (recently around 3.9 million). Agenus's SIR currently stands at 5.95. In other words for every 100,000 Agenus shares traded daily on the market, roughly 5950 shares are currently held short.

However Agenus's short interest can also be evaluated against the total number of Agenus shares, or, against the total number of tradable Agenus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Agenus's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Agenus shares in existence, roughly 130 shares are currently held short) or 0.1412% of the tradable shares (for every 100,000 tradable Agenus shares, roughly 141 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Agenus.

Find out more about how you can short Agenus stock.

Agenus share dividends

We're not expecting Agenus to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Have Agenus's shares ever split?

Agenus's shares were split on a 1:6 basis on 3 October 2011. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Agenus shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Agenus shares which in turn could have impacted Agenus's share price.

Agenus share price volatility

Over the last 12 months, Agenus's shares have ranged in value from as little as $1.82 up to $5.63. A popular way to gauge a stock's volatility is its "beta".

AGEN.US volatility(beta: 1.96)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agenus's is 1.9592. This would suggest that Agenus's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Agenus overview

Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site